GILENYACONNECT: the patient support programme which offers patients and healthcare professionals access to nurses and specially developed materials.
GILENYACONNECT is a patient support programme, offering patients and healthcare professionals unique access to a dedicated and experienced nurse support team and a range of specially developed materials to help patients through the first year of their GILENYA journey.
GILENYACONNECT provides UK centres with specialist nurse support for GILENYA pre-initiation, first-dose observation and first-year monitoring.
This flexible programme allows you to choose the components which best suit the needs of your centre.
Since the inception of GILENYA CONNECT, many RRMS patients have benefited from our services:
*As of the end of December 2018 since the beginning of the service.
GILENYA CONNECT Case Studies
Read opinions and experiences from centres where Gilenya Connect is live below.
Survey results from patients enrolled in the GILENYACONNECT programme1
HCPs highlighted that this programme helped MS centres to effectively manage workload and provided a safety net when and where patients required it.1
The majority of HCPs were totally satisfied with the quality of contact received as part of the GILENYACONNECT service.2
GILENYACONNECT is a healthcare service that is offered as a programme for patients prescribed GILENYA. It is not intended to replace the services of the patient’s NHS medical team.
Gd+: gadolinium enhancing; HCP: healthcare professional; MRI: magnetic resonance imaging; RES: rapidly evolving severe; RRMS: relapsing remitting multiple sclerosis.
Indication: GILENYA is indicated as a single disease modifying therapy in highly active RRMS for the following groups of adult patients and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with ≥1 disease modifying therapy, or patients with RES RRMS deﬁned by ≥2 disabling relapses in 1 year, and with 1 or more Gd+ lesions on brain MRI or a signiﬁcant increase in T2 lesion load as compared to a previous recent MRI.3
- Data on File.
- Wong O and Ayer M. GilenyaConnect: Patient and healthcare professional satisfaction feedback. Poster.
- GILENYA (fingolimod) Summary of Product Characteristics.